Key result
A booster dose of S-268019-b was safe and enhanced SARS-CoV-2 neutralizing antibodies, IgG antibodies, and T-helper 1-mediated immune reactions in Japanese adults with prior mRNA vaccination.
Why the study?
Booster vaccination has become increasingly important against SARS-CoV-2 variants with immune-escaping capacity despite the initial success of primary vaccines.
Does S-268019-b booster improve immunogenicity and maintain safety in Japanese adults previously vaccinated with mRNA vaccines?
Does S-268019-b booster improve immunogenicity and maintain safety in Japanese adults previously vaccinated with mRNA vaccines?
S-268019-b as a booster dose is safe and immunogenic in Japanese adults previously vaccinated with mRNA vaccines.
Answers are grounded in this paper and cite their sources.
Supports S-268019-b booster immunogenicity in mRNA recipients; leaves open randomized confirmation before practice change.
Despite the initial success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in prevention of symptomatic and severe diseases, booster vaccination has become increasingly important with the advent of variants with immune-escaping capacity. Herein, we report the safety and immunogenicity of S-268019-b, comprising SARS-CoV-2 spike protein and a squalene-based adjuvant, as a booster dose. We performed an interim analysis of an open-label, Phase 3 study data until Day 29 following S-268019-b booster in Japanese adults (aged 20-64 years) who had completed primary vaccination with mRNA-1273 and in Japanese elderly (aged ≥ 65 years) who had completed primary vaccination with mRNA-1273 or BNT162b2. Reactogenicity was mild in most participants; no serious treatment-related adverse events were noted. S-268019-b enhanced SARS-CoV-2 neutralizing antibodies, immunoglobulin G antibodies, and predominant T-helper 1-mediated immune reaction in all cohorts, regardless of age, in Japanese participants with prior vaccination with mRNA vaccines.
No takes yet. Share an insight, caveat, or question.
Sonoyama et al. (2023) studied SARS-CoV-2. S-268019-b was evaluated on Safety and immunogenicity (neutralizing antibodies, immunoglobulin G antibodies, and T-helper 1-mediated immune reaction). A booster dose of S-268019-b was safe and enhanced SARS-CoV-2 neutralizing antibodies, IgG antibodies, and T-helper 1-mediated immune reactions in Japanese adults with prior mRNA vaccination.
Synapse has enriched 10 related papers. Consider them for comparative context: